The Epilepsy Foundation of America® is the national voluntary agency dedicated solely to the welfare of the more than 2 million people with epilepsy in the U.S. and their families. The organization works to ensure that people with seizures are able to participate in all life experiences; to improve how people with epilepsy are perceived, accepted and valued in society; and to promote research for a cure. In addition to programs conducted at the national level, epilepsy clients throughout the United States are served by 47 Epilepsy Foundation affiliates around the country.
In 2013, the Epilepsy Foundation merged with the Epilepsy Therapy Project to bring a stronger focus on accelerating new therapies in a timeframe that matters to individuals living with epilepsy today, as well as sharpens organizational focus on education, awareness and advocacy.
The new Epilepsy Foundation brings together the mission and assets of both organizations:
The Epilepsy Foundation was established in 1967 as the Epilepsy Foundation of America, merging two largely regional epilepsy organizations. It began operating as the Epilepsy Foundation on January 1, 1998, formalizing the name most often used by the public in referring to the organization. It is a 501(c)(3) tax-exempt charitable organization existing under the laws of the State of Delaware, with a national office in metropolitan Washington, D.C.
The Foundation is governed by a Board of Directors comprising business leaders, health care professionals and client representatives. The national board of directors is chaired by Warren Lammert, business investor, and founder of the Epilepsy Therapy Project. The Foundation’s professional advisory board is chaired by Joseph Sirven, M.D., Professor of Neurology and Chairman of the Department of Neurology at the Mayo Clinic in Arizona.
The Epilepsy Foundation is funded primarily through individual donations from the general public and receives restricted grant support from the federal government, foundations and private industry. The organization is a participant in the Combined Federal Campaign and a member of the National Health Council and of the International Bureau for Epilepsy.
To invest your contributions effectively, we have assembled an outstanding staff and team of clinicians, researchers, and pharmaceutical, biotechnology, and finance industry advisors. These scientific and business advisory board members make funding decisions and provide support to advance the most promising new therapy projects.